NLS Pharmaceutics Submits 3 Abstracts for 2025 ASCP Meeting
January 30, 2025
NLS Pharmaceutics Ltd, a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission